Jiri Emmer, Zentiva’s director for strategic marketing said for Pravo daily that Zentiva will remain a generic drug producer and it cannot afford original research. Emmer added that the company will launch a anti-osteoporotic drug that is cheaper than its original in autumn. Zentiva plans to double its sales in the Baltics in the next two years while it was the fastest growing company in Lithuania in the 1Q2005. Zentiva's market share in the Baltic stays at c1%.